Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682658 | 0.84 | L3MBTL1 (0.71) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL7371767 | 0.84 | F2 (0.46) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL27782216 | 0.81 | DAO (0.61) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL2653702 | 0.79 | DAO (0.62) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL864408 | 0.79 | DAO (0.62) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL335624 | 0.76 | DAO (0.64) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL7008751 | 0.76 | DAO (1.00) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL2653016 | 0.74 | DAO (0.56) | DAOHPGDTSHRMAPK1ATM | |
| SCHEMBL28267961 | 0.74 | DAO (0.77) | DAOHPGDTSHRMAPK1ATM | |
| Alcohol SCHEMBL28943550 | 0.73 | DAO (0.60) | DAOHPGDPKMLIG1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1511740-B1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY PATENT DIVISON (US) | 2006-06-22 | — | — | US | disclosed |
| EP-1587905-A3 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1587905-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1511740-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004063348-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | DAO 4022/4885HPGD 359/4885TSHR 458/4885 |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | DAO 3846/4885HPGD 573/4885TSHR 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.